Company news
Alterity Therapeutics Ltd. (ASX:ATH) news
Alterity Therapeutics Ltd. news releases on 6ix. Latest, Jul 30, 2025: Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
Press releases — page 2
Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
July 30, 2025
Alterity Therapeutics : Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
July 29, 2025
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
July 28, 2025
Positive ATH434 Results from Open-Label Phase 2 Trial in MSA
July 28, 2025
Alterity Therapeutics : Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
July 27, 2025
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
July 24, 2025
Peer-Reviewed Publication on Novel MRI Endpoint from bioMUSE
July 24, 2025
Response to ASX Price Query
July 13, 2025
Alterity Therapeutics to Provide Corporate Update in Fireside Chat
June 23, 2025
Alterity Therapeutics Prominently Featured at the International MSA Congress
May 12, 2025
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
May 7, 2025
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
May 5, 2025
Alterity Granted U.S. FDA Fast Track Designation for ATH434
May 4, 2025
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
April 30, 2025
Alterity Therapeutics : Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
April 29, 2025
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
April 28, 2025
Options Prospectus
April 17, 2025
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
April 10, 2025
Alterity Phase 2 Presentation at AAN 2025
April 10, 2025
Alterity Presents Encouraging New Phase 2 Data in MSA
April 10, 2025
Alterity Therapeutics : Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
April 9, 2025
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
April 3, 2025
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
March 27, 2025
Alterity Completes Last Patient Visit in Open-Label Trial
March 27, 2025
Alterity raises A$40m to Advance ATH434 Development in MSA
February 9, 2025
Alterity Raises Funds for ATH434 BD and Clinical Activities
February 2, 2025
Positive ATH434 Phase 2 Results Led By Clinical Efficacy
January 29, 2025
Alterity Announces Completion of Phase 2 Clinical Trial
December 3, 2024
Appendix 4E Preliminary Final Report
August 29, 2024
Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
July 17, 2024
Alterity Receives a $3.9 million R&D Tax Incentive Refund
March 26, 2024
Alterity Therapeutics Raises $3.25 M AUD in Placement
February 22, 2024
Phase 2 DMC Recommends Continuing Clinical Trial as Planned
February 6, 2024
Positive Efficacy Data for ATH434 in a Primate Model of PD
December 3, 2023
Alterity Therapeutics Raises $4.8M AUD in Placement
November 21, 2023
ATH completes enrolment in ATH434-201 Phase 2 clinical trial
November 7, 2023
Appendix 4E and Annual Report 2023
August 31, 2023
Alterity Presents New Data on Multiple System Atrophy
August 31, 2023
Alterity Granted New Composition of Matter Patent in Europe
August 23, 2023
Alterity receives a $4.74 million R&D Tax Refund
August 15, 2023
Ph 2 Data Monitoring Committee Recommends Continuing Trial
July 26, 2023
Investor Presentation
June 22, 2023
ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder
May 30, 2023
Appendix 4C and Quarterly Cash Flow Report
April 27, 2023
US patent grant and license agreement
March 14, 2023
First Patient Enrolled in Europe in Phase II Clinical trial
March 7, 2023
Regulatory approval for Phase II trial in France and Austria
February 16, 2023
ATH434 Clinical Trial Launched in Italy
January 24, 2023
ATH434 clinical trial launched in the US
January 9, 2023
New US patent for compounds to treat neurodegeneration
December 29, 2022